Prizlon-cel CAR T cells for large B-cell lymphoma that returned after approved CAR T
Tests prizlon-cel in adults whose lymphoma came back after CAR T therapy.
Key facts
- Who runs it
- AbelZeta Inc.
- Where
- Gilbert and La Jolla, United StatesSee the 2 sites
- Trial code
- Registry title
- Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 55 people, planned
- Starts
- May 2027
- Expected to end
- Dec 2030
- Type of study
- Interventional
- Treatments tested
- Prizloncabtagene Autoleucel
- Record updated
- 15 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose large B-cell lymphoma came back or did not respond after at least 2 earlier treatments, including an approved CAR T-cell therapy.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Relapsed or refractory B-cell non-Hodgkin lymphoma, such as diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, high-grade B-cell lymphoma or follicular large B-cell lymphoma. Disease must be measurable (Lugano 2014).
- Earlier treatment
- At least 2 lines of standard therapy, including an FDA approved, commercially available CAR T-cell therapy, given at least 3 months before.
Main reasons for not taking part
- Prior allogeneic hematopoietic stem cell transplantation (HSCT)
- Autologous stem cell transplant (ASCT) within 12 weeks of leukapheresis
- Prior treatment with any investigational CAR T-cell therapy
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Able to sign and date the Informed Consent Form (ICF)
- ≥18 years of age, at the time of signing informed consent
- Diagnosis of B-cell non-Hodgkin lymphoma (B-NHL), including the following neoplasms as defined by the 2022 WHO classification of lymphoid neoplasms:; Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS); Primary mediastinal large B-cell lymphoma (PMBCL); Transformed follicular lymphoma (tFL) (Pathology report is required to clarify DLBCL rather than follicular lymphoma (FL) with local/minor progression to DLBCL); Diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements (DLBCL/HGBL-MYC/BCL2); High-grade B-cell lymphoma (HGBL), NOS; Follicular large B-cell lymphoma (FLBL) (At least 2 pathological diagnoses of follicular lymphoma grade 3B [FL3b] at different times are required, and the most recent pathology used for screening is FL3b or FLBL)
- R/R disease after ≥2 lines of standard therapy, including FDA approved, commercially available CAR T-cell therapy for at least 3 months since previous CAR T-cell therapy treatment
- Measurable disease per the Lugano 2014 Classification
Who cannot take part
- Prior allogeneic hematopoietic stem cell transplantation (HSCT)
- Prior treatment with any investigational CAR T-cell therapy
- ASCT within 12 weeks of leukapheresis
Where in United States
- Gilbert, ArizonaHospital not named in the registryContact: Kirstin Liechty, Head of Clinical OperationsNo longer taking part
- La Jolla, CaliforniaHospital not named in the registryContact: Kirstin Liechty, Head of Clinical OperationsNo longer taking part
About the trial
What the trial wants to find out
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of Prizloncel, an anti-CD19/CD20 chimeric antigen receptor T cells following lymphodepleting chemotherapy in participants with relapsed/refractory (r/r) diffuse large B-cell lymphoma post FDA approved, commercially available CAR T-cell therapy
Read full original descriptionShow less
Approximately 50 participants will undergo leukapheresis, lymphodepletion with fludarabine and cyclophosphamide, and infusion of Prizlon-cel. Participants will be followed for 24 months (approximately 2 years) to evaluate efficacy, safety, CAR T-cell persistence, pharmacokinetics/pharmacodynamics, and biomarkers. Long-term safety follow-up for gene therapy-related events will continue for up to 15 years following CAR T-cell infusion.
The group in the trial
- Prizlon-celTreatment being tested
Participants will receive: • Leukapheresis • Fludarabine • Cyclophosphamide • Single intravenous infusion of Prizlon-cel.
Treatment: Prizloncabtagene Autoleucel
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multi-center, Phase 2 Clinical Study of an Autologous Anti-CD19/CD20 Chimeric Antigen Receptor T-Cell Therapy, Prizloncabtagene Autoleucel (Prizlon-cel), for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
- Plain-language title
- Prizlon-cel CAR T cells for large B-cell lymphoma that returned after approved CAR TGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 15 October 2026